Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

Alex Barnes, Dirk Hofmann, Lesley Ann Hall, Sonja Klebe, Réme Mountifield

Research output: Contribution to journalArticlepeer-review

Abstract

Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.

Original languageEnglish
Pages (from-to)447-448
Number of pages2
JournalAnnals of Gastroenterology
Volume34
Issue number3
DOIs
Publication statusE-pub ahead of print - 27 Jan 2021

Keywords

  • Colitis
  • Esophagitis
  • Immunotherapy
  • Inflammatory bowel disease
  • Ocrelizumab

Fingerprint

Dive into the research topics of 'Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis'. Together they form a unique fingerprint.

Cite this